Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug

References

• Basic Information about HIV and AIDS. [cited 11 Apr 2012]; Available from: (http://www.cdc.gov/hiv/topics/basic/index.htm).
   Google Scholar
• Katzung BG. Basic & clinical pharmacology. 10th ed. New York: McGraw-Hill; 2007, p. 1088.
   Google Scholar
• Zhang L, Zhang Y, Huang SM. Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. Mol Pharm. 2009;6:1766–1774.
   PubMed Web of Science ®Google Scholar
• Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42:3218–3224.
   PubMed Web of Science ®Google Scholar
• Kumar GN, Jayanti VK, Johnson MK, et al. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm Res. 2004;21:1622–1630.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Pal D, Mitra AK. Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm. 2007;339:139–147.
   PubMedGoogle Scholar
• Sakuma S, Matsumoto S, Ishizuka N, et al. Enhanced boosting of oral absorption of Lopinavir through electrospray coencapsulation with ritonavir. J Pharm Sci. 2015;104:2977–2985.
   PubMed Web of Science ®Google Scholar
• Youle M, Mocroft A, Johnson M, et al. Lipid profiles in patients on ritonavir/indinavir containing salvage regimens. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 1999, San Diego, USA.
   Google Scholar
• Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet. 2005;365:682–686.
   PubMed Web of Science ®Google Scholar
• Cooper CL, van Heeswijk RP, Gallicano K, et al. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis. 2003;36:1585–1592. 15
   PubMed Web of Science ®Google Scholar
• Agarwal S, Boddu SH, Jain R, et al. Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor. Int J Pharm. 2008;359:7–14.
   PubMed Web of Science ®Google Scholar
• Aji Alex MR, Chacko AJ, Jose S, et al. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci. 2011;42:11–18.
   PubMed Web of Science ®Google Scholar
• Joshi G, Kumar A, Sawant K. Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles. Drug Deliv. 2016;23:3492–3504.
   PubMed Web of Science ®Google Scholar
• Nassar T, Rom A, Nyska A, et al. A novel nanocapsule delivery system to overcome intestinal degradation and drug transport limited absorption of P-glycoprotein substrate drugs. Pharm Res. 2008;25:2019–2029.
   PubMed Web of Science ®Google Scholar
• Nassar T, Rom A, Nyska A, et al. Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. J Control Release. 2009;133:77–84.
   PubMed Web of Science ®Google Scholar
• Saitoh H, Saikachi Y, Kobayashi M, et al. Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine. Eur J Pharm Sci. 2006;28:34–42.
   PubMed Web of Science ®Google Scholar
• Yokogawa K, Takahashi M, Tamai I, et al. P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharm Res. 1999;16:1213–1218.
   PubMed Web of Science ®Google Scholar
• Nassar T, Attili-Qadri S, Harush-Frenkel O, et al. High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation. Cancer Res. 2011;71:3018–3028.
   PubMed Web of Science ®Google Scholar
• Donato EM, Martins LA, Fröehlich PE, et al. Development and validation of dissolution test for lopinavir, a poorly water-soluble drug, in soft gel capsules, based on in vivo data. J Pharm Biomed Anal. 2008;47:547–552.
   PubMed Web of Science ®Google Scholar
• Kimpton J, Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated 3-galactosidase gene. J Virol 1992;66:2232–2239.
   PubMed Web of Science ®Google Scholar
• Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25:999–1022.
   PubMed Web of Science ®Google Scholar
• Imperiale JC, Nejamkin P, del Sole MJ, et al. Novel protease inhibitor-loaded nanoparticle-in-microparticle delivery system leads to a dramatic improvement of the oral pharmacokinetics in dogs. Biomaterials. 2015;37:383–394.
   PubMed Web of Science ®Google Scholar
• Augustine R, Ashkenazi DL, Arzi RS, et al. Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination. Acta Biomater. 2018;74:344–359.
   PubMed Web of Science ®Google Scholar
• du Plooy M, Viljoen M, Rheeders M. Evidence for time-dependent interactions between ritonavir and lopinavir/ritonavir plasma levels following P-glycoprotein inhibition in Sprague-Dawley rats. Biol Pharm Bull. 2011;34:66–70.
   PubMed Web of Science ®Google Scholar
• Lal R, Hsu A, Granneman GR, et al. Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir. The 5th Conference on Retroviruses and Opportunistic Infections, 1998, Chicago, USA.
   Google Scholar
• Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med. 2001;344:984–996.
   PubMed Web of Science ®Google Scholar
• Magalhaes NS, Fessi H, Puisieux F, et al. An in-vitro release kinetic examination and comparative evaluation between submicron emulsion and polylactic acid nanocapsules of clofibride. J Microencapsul. 1995;12:195–205.
   PubMed Web of Science ®Google Scholar